Peripheral Blood Stem Cell Mobilization With Filgrastim in Patients With Chronic Myeloid Leukemia in Cytogenetic Response
- Determine the feasibility and safety of harvesting adequate numbers of CD34-positive
peripheral blood stem cells using filgrastim (G-CSF) in patients with chronic phase
chronic myeloid leukemia in complete cytogenetic remission.
- Determine the safety of temporarily discontinuing treatment with imatinib mesylate and
using G-CSF during the harvesting procedure, in terms of the percentage of Philadelphia
chromosome (Ph)-positive cells before and after stem cell harvest, in these patients.
OUTLINE: Patients receive filgrastim (G-CSF) and then undergo apheresis for up to 5 days.
After completion of apheresis, patients resume treatment with imatinib mesylate off study.
Patients may later undergo autologous peripheral blood stem cell transplantation, when
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 2 years.
Masking: Open Label, Primary Purpose: Treatment
Feasibility and safety of harvesting chronic myeloid leukemia (CML) patients in continuous complete remission (CCR) by adequate CD34+ stem cell numbers post-harvest
Gwen L. Nichols, MD
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center||New York, New York 10032|